Xenitra secures A$5M medical nutrition supply deal, deepening Fukang healthcare pipeline
Xenitra (ASX:XEN) has signed a three-year Framework Purchase Agreement through its Hong Kong subsidiary, Hong Kong Fukang Trade Limited, targeting A$5 million in aggregate procurement of Food for Special Medical Purposes (FSMP) products. The agreement runs from 12 August 2026 to 12 August 2029.
The buyer under the framework is JOY CHARM LIMITED. Importantly, the A$5 million figure is a target aggregate procurement amount and not a guaranteed minimum purchase obligation.
This latest development follows the recently announced A$12 million Kangsheng pharmaceutical procurement agreement, marking two contracts building the Fukang commercial pipeline in quick succession. Both agreements further validate the Fukang acquisition and expand the addressable revenue base being developed through the subsidiary.
When big ASX news breaks, our subscribers know first
What the Joy Charm agreement delivers
The agreement operates as a framework structure. Specific products, quantities, pricing and delivery schedules are set through individual Purchase Orders, with FSMP purchases under those orders contributing toward the aggregate procurement target.
The payment structure is designed to keep the cash-to-cash cycle in line with the broader OTC medicine division:
-
20% of each Purchase Order is payable within seven days after execution and receipt of invoice.
-
80% is payable within seven days following receipt of the required commercial and shipping documentation.
This staged approach supports working capital management across the platform, aligning the timing of cash outflows with delivery milestones.
| Key Term | Summary |
|---|---|
| Parties | Seller: Hong Kong Fukang Trade Limited. Buyer: JOY CHARM LIMITED. |
| Term | Three years, from 12 August 2026 to 12 August 2029. |
| Procurement target | Target aggregate purchases of A$5 million of FSMP products. The amount is a target, not a guaranteed minimum purchase obligation. |
| Products | Food for Special Medical Purposes (FSMP). Specifications, quantities and unit prices set through individual Purchase Orders. |
| Payment terms | 20% on Purchase Order execution and invoice; 80% on receipt of shipping documentation. |
| Governing law / disputes | PRC law. Disputes submitted to the China International Economic and Trade Arbitration Commission (CIETAC), Beijing. |
Understanding FSMP: the fast-growing category behind the deal
Food for Special Medical Purposes (FSMP) are specialised medical nutrition products. They sit apart from conventional over-the-counter (OTC) medicines, forming an adjacent healthcare and nutrition category.
The significance for Xenitra lies in the expansion strategy. The agreement broadens Fukang beyond conventional OTC medicines while leveraging the same sourcing, regulatory, logistics and commercial infrastructure already in place.
According to State Administration for Market Regulation (SAMR) data cited by the Company, the China FSMP market has shown notable growth:
-
Grew from approximately RMB7 billion (A$1.5 billion) in 2020 to approximately RMB23 billion (A$4.8 billion) in 2024.
-
This represents annualised growth of more than 25%.
-
National FSMP imports increased by approximately 50% between 2021 and 2023.
-
From 2024, China reduced import tariffs to zero for FSMP products for people aged over three years, extending existing zero-tariff treatment for infant FSMP products.
A large, structurally growing and import-friendly market provides a credible growth backdrop for the A$5 million target, though realisation remains subject to execution of individual Purchase Orders.
The broader OTC medicine opportunity
Xenitra’s existing exposure to China’s OTC medicines market provides additional context for the Fukang platform’s addressable base. The Chinese OTC market was estimated at approximately RMB400 billion in 2023, representing annual growth of approximately 9.1%.
OTC medicines also accounted for approximately 43% of retail pharmacy medicine sales in 2024. China’s expanding online pharmacy channel offers a further growth platform, supported by an established National Medical Products Administration (NMPA) regulatory framework for online medicine sales.
Why this matters for Xenitra’s investment case
The agreement connects to Xenitra’s three growth pillars, all now in commercial execution as FY27 begins: the Fukang healthcare platform, the established Nutritionals business, and the OPAL real-world-asset (RWA) tokenised sales platform.
Momentum is evident in early trading. Following its acquisition and post-merger integration in June, Fukang achieved sales of over A$450k AUD in July, complementing the contracted procurement agreements.
Non-Executive Chairman, Dr Anthony Noble
“Following the acquisition of Fukang, integration and a strong first month sales the A$12 million Kangsheng agreement announced recently and this new A$5 million procurement framework represents further positive steps in building the commercial pipeline through Fukang and demonstrate the breadth of opportunity that acquisition has created for Xenitra. Our ability to operate in the pharmaceutical market also remains an, as yet, untapped revenue stream.”
Dr Noble also pointed to the strategic fit of the new category, noting that FSMP and specialised nutrition are areas that align with Xenitra’s strengths in Nutritionals and OTC Medicine. The A$5 million figure remains a target aggregate rather than a guaranteed minimum purchase obligation.
What comes next
Value under the agreement will be realised progressively through the execution of individual Purchase Orders across the three-year term ending 12 August 2029.
The two agreements now in place, the A$12 million Kangsheng pharmaceutical framework and the A$5 million Joy Charm FSMP framework, together demonstrate the potential of Fukang’s sourcing, logistics and commercial infrastructure to support multiple products and counterparties. The repeatable framework structure suggests additional counterparties could be onboarded onto the same platform over time.
The Biomiq Skincare distribution deal, signed in June 2026 for a four-year exclusive Greater China arrangement with A$5 million in minimum offtake, illustrated how Xenitra applies the same framework contracting structure across different product verticals, with that agreement also routed through the OPAL tokenised ecosystem.
The A$12 million Kangsheng pharmaceutical procurement agreement, also structured as a three-year framework running to July 2029, carries a guaranteed minimum purchase obligation rather than a target figure, a structural distinction that sets the two contracts apart in terms of revenue certainty.
Management has also flagged the pharmaceutical market as an as yet untapped revenue stream, pointing to a potential future avenue for growth alongside the contracted procurement agreements already secured.
Don’t Miss the Next Healthcare Winner on ASX
Big News Blast delivers FREE breaking ASX healthcare and consumer news directly to your inbox within minutes of release, complete with in-depth analysis. Over 20,000 subscribers are already staying ahead of the market. Click the “Free Alerts” button at Big News Blast to get the next market-moving announcement the moment it drops.